Suur Biliciler, MD
Neuromuscular Medicine · Houston, TXNPI 1588819379
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.8%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by UCB, Inc. at 43.8% of the total. 2025 is the largest year on record at $31,274, more than ten times the $181 reported in 2019.
Across 135 payments — averaging $275.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$16K
- Amgen$9K
- Pfizer$7K
- Argenx US, Inc.$3K
- Sanofi$251
- Takeda Pharmaceuticals U.S.A., Inc.$193
- plus $1K from 16 others
Across 250 payments — averaging $5803.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$1.3M
- Argenx US, Inc.$63K
- UCB SA$51K
- Janssen Research & Development, LLC$19K
What the payments were for
- Consulting fees$18,14049%
- Speaking & faculty fees$12,00032%
- Travel & lodging$2,9888%
- Food & beverage$4,02111%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 33 | $16,289 |
| Amgen(2 entities) | 9 | $8,684 |
| Pfizer | 14 | $7,401 |
| Argenx US, Inc. | 25 | $3,172 |
| Sanofi | 3 | $251 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $193 |
| AstraZeneca | 9 | $188 |
| CSL Behring | 7 | $140 |
| Grifols USA, LLC | 5 | $140 |
| Janssen Research & Development, LLC | 1 | $128 |
| Octapharma USA, Inc. | 1 | $112 |
| Hospira, Inc. | 5 | $109 |
| AbbVie(2 entities) | 4 | $81 |
| Biogen | 5 | $79 |
| Sarepta Therapeutics, Inc. | 1 | $36 |
| Strongbridge US Inc. | 2 | $33 |
| EDW Pharma, Inc. | 1 | $32 |
| Catalyst Pharmaceuticals, Inc. | 2 | $27 |
| Advanced Respiratory, Inc | 1 | $26 |
| Greenwich Biosciences, Inc. | 1 | $15 |
| Tanabe Pharma America, Inc. | 1 | $12 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rystiggo$11,129
- UPLIZNA$8,527
- Zilbrysq$4,432
- VYVGART$1,554
- VYVGART HYTRULO$971
- OCTAGAM IMMUNE GLOBULIN (HUMAN)$805
- GAMMAGARD$124
- PANZYGA$112
- NEXVIAZYME$112
How this compares
Too few neuromuscular medicine providers in Texasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 105 | $698,033 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 98 | $608,877 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 30 | $365,506 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 20 | $224,845 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 39 | $217,980 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 17 | $217,342 |
| Pyridostigmine Bromide | 49 | $3,679 |
| Gabapentin | 67 | $960 |
| Methylprednisolone Sodium SuccMethylprednisolone Sod Succ | 39 | $936 |
| Prednisone | 81 | $762 |
| Azathioprine | 29 | $294 |
| Duloxetine Hcl | 17 | $220 |
| Sodium Chloride0.9 % Sodium Chloride | 73 | $212 |
| Baclofen | 19 | $124 |
| Ondansetron HclOndansetron Hcl/Pf | 19 | $53 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringPrivigen | $140 | $698,033105 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $193 | $608,87798 claims |
| Grifols USA, LLCGamunex-C | $140 | $224,84520 claims |
| PfizerOctagam | $7,401 | $217,98039 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neuromuscular medicine providers in Texason file to place this against a meaningful peer group, so we don't.
Other neuromuscular medicine in Houston
- Ashley AndersonHouston$76K
- Anita MadanHouston$3K
- Nicolaas AndersonHouston$42
- Yessar HussainAustin$127K
- Matthew WicklundSan Antonio$110K
- Ratna Bhavaraju SankaSan Antonio$56K
- Hakam AsaadDallas$8K
- Darine KassarSugar Land$6K
- Niloofar YariDallas$5K
- George CreelTemple$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.